恆瑞醫藥(600276.SH):全資子公司擬與江蘇恆瑞關聯自然人孫飄揚共同投資設立公司
格隆匯 7 月 6日丨恆瑞醫藥(600276.SH)公佈,江蘇恆瑞醫藥股份有限公司(以下簡稱“江蘇恆瑞”或“公司”)之全資子公司上海恆瑞醫藥有限公司(以下簡稱“上海恆瑞”)擬與江蘇恆瑞的關聯自然人孫飄揚共同出資設立瑞利迪(上海)生物醫藥有限公司(以工商機關正式核准的名稱為準)(以下簡稱“瑞利迪”)。瑞利迪的註冊資本為人民幣10,000萬元,其中,上海恆瑞認繳出資6,000萬元,佔註冊資本的60%;孫飄揚先生認繳出資4,000萬元,佔註冊資本的40%。
上海恆瑞為公司的全資子公司,孫飄揚先生為公司實際控制人及公司董事,本次交易構成關聯交易。上述事項已經公司第八屆董事會第四次會議審議通過,根據《上市公司重大資產重組管理辦法》,本次交易不構成重大資產重組,不需要經過有關部門批准。該事項無須提交公司股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.